Clinical efficacy of Eribulin new for metastatic breast cancer

Clinical efficacy of Eribulin new for metastatic breast cancer - Clinical efficacy of Eribulin new for metastatic breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014445

Enrollment

120

Registered

2014-07-01

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

progressive or metastatic breast cancer patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: For breast cancer metastasis cases, cases it was invalid be administered an anti-cancer agent anthracycline, taxane-based in the designated facilities.

Exclusion criteria

Exclusion criteria: Patients who sustain adverse events using after taxanes. Patients who have not enough judgment ability minors, in adults, cases of acquisition agreement by the description document is difficult. Patients who are subjected to treatment without their doctors not revealing the breast cancer treatment.

Design outcomes

Primary

Measure	Time frame
OS,PFS	—

Secondary

Measure	Time frame
ORR,TTF,adverse ebents	—

Countries

Japan

Contacts

Public ContactKikuchi Yasuko

Graduate School of Medicine and Faculty of Medicine, the University of Tokyo Breast and Endocrine Surgery Department

kikuchiy-sur@h.u-tokyo.ac.jp03-5800-9538

Outcome results